drugset / Trial / NCT05205109
A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors
NaSequentialOpen-labelTreatment
Summary
This is a study of ATG-037 Monotherapy and Combination Therapy with Pembrolizumab in Patients with Locally Advanced or Metastatic Solid Tumors
Timeline
- Start
- 2022-06-07
- Primary completion
- 2027-08-30
- Completion
- 2028-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ATG-037 | Unknown | — | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | — |
Indications
No indication recorded.